Literature DB >> 23565581

Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.

Taylor Harrison1, Sachiko Miyahara, Anthony Lee, Scott Evans, Barbara Bastow, David Simpson, Ian Gilron, Robert Dworkin, Eric S Daar, Linda Wieclaw, David B Clifford.   

Abstract

OBJECTIVE: There is limited evidence for efficacy of analgesics as monotherapy for neuropathic pain associated with HIV-associated polyneuropathies, in spite of demonstrated efficacy in other neuropathic pain conditions. We evaluated the tolerability and analgesic efficacy of duloxetine, methadone, and the combination of duloxetine-methadone compared with placebo.
DESIGN: This study was a phase II, randomized, double-blind, placebo-controlled, four-period crossover multicenter study of analgesic therapy for patients with at least moderate neuropathic pain due to HIV-associated polyneuropathy. Duloxetine, methadone, combination duloxetine-methadone, and placebo were administered in four different possible sequences. The primary outcome measure was mean pain intensity (MPI) measured daily in a study-supplied pain diary.
RESULTS: A total of 15 patients were enrolled from eight study sites and eight patients completed the entire trial. Study treatments failed to show statistically significant change in MPI compared with placebo. Adverse events were frequent and associated with high rates of drug discontinuation and study dropout.
CONCLUSIONS: Challenges with participant recruitment and poor retention precluded trial completion to its planned targets, limiting our evaluation of the analgesic efficacy of the study treatments. Challenges to successful completion of this study and lessons learned are discussed. Wiley Periodicals, Inc.

Entities:  

Keywords:  Antidepressants; HIV; Neuropathic Pain; Opioids

Mesh:

Substances:

Year:  2013        PMID: 23565581      PMCID: PMC4207215          DOI: 10.1111/pme.12084

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  41 in total

1.  Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Authors:  Ronald J Ellis; Debralee Rosario; David B Clifford; Justin C McArthur; David Simpson; Terry Alexander; Benjamin B Gelman; Florin Vaida; Ann Collier; Christina M Marra; Beau Ances; J Hampton Atkinson; Robert H Dworkin; Susan Morgello; Igor Grant
Journal:  Arch Neurol       Date:  2010-05

2.  A flood of opioids, a rising tide of deaths.

Authors:  Susan Okie
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 91.245

3.  The evidence for pharmacological treatment of neuropathic pain.

Authors:  Nanna Brix Finnerup; Søren Hein Sindrup; Troels Staehelin Jensen
Journal:  Pain       Date:  2010-09       Impact factor: 6.961

4.  Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy.

Authors:  J Robinson-Papp; S Morgello; F Vaida; C Fitzsimons; D M Simpson; K J Elliott; M Al-Lozi; B B Gelman; D Clifford; C M Marra; J A McCutchan; J H Atkinson; R H Dworkin; I Grant; R Ellis
Journal:  Pain       Date:  2010-09-20       Impact factor: 6.961

5.  Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.

Authors:  D I Abrams; C A Jay; S B Shade; H Vizoso; H Reda; S Press; M E Kelly; M C Rowbotham; K L Petersen
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

6.  Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.

Authors:  D M Simpson; G Schifitto; D B Clifford; T K Murphy; E Durso-De Cruz; P Glue; E Whalen; B Emir; G N Scott; R Freeman
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

7.  Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato; Roberto Occhioni; Gianni Colini Baldeschi; Carlo Reale
Journal:  Eur Neurol       Date:  2008-12-18       Impact factor: 1.710

8.  Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.

Authors:  David M Simpson; Stephen Brown; Jeffrey Tobias
Journal:  Neurology       Date:  2008-06-10       Impact factor: 9.910

9.  Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.

Authors:  Ian Gilron; Joan M Bailey; Dongsheng Tu; Ronald R Holden; Alan C Jackson; Robyn L Houlden
Journal:  Lancet       Date:  2009-09-30       Impact factor: 79.321

Review 10.  Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Tudor J C Phillips; Catherine L Cherry; Sarah Cox; Sarah J Marshall; Andrew S C Rice
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

View more
  7 in total

Review 1.  Drug combinations in the treatment of neuropathic pain.

Authors:  Elon Eisenberg; Erica Suzan
Journal:  Curr Pain Headache Rep       Date:  2014-12

Review 2.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

Review 3.  Update of HIV-Associated Sensory Neuropathies.

Authors:  Angela Aziz-Donnelly; Taylor B Harrison
Journal:  Curr Treat Options Neurol       Date:  2017-08-31       Impact factor: 3.598

Review 4.  2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.

Authors:  R Douglas Bruce; Jessica Merlin; Paula J Lum; Ebtesam Ahmed; Carla Alexander; Amanda H Corbett; Kathleen Foley; Kate Leonard; Glenn Jordan Treisman; Peter Selwyn
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

5.  Improved therapeutic potential of tapentadol employing cationic exchange resins as carriers in neuropathic pain: evidence from pharmacokinetic and pharmacodynamics study.

Authors:  Manu Sharma; Ranju Soni
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

Review 6.  Understanding the etiology and management of HIV-associated peripheral neuropathy.

Authors:  Kara Stavros; David M Simpson
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.495

7.  Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis.

Authors:  Aikaterini Amaniti; Chrysanthi Sardeli; Varvara Fyntanidou; Panagiota Papakonstantinou; Ioannis Dalakakis; Antonios Mylonas; Konstantinos Sapalidis; Christoforos Kosmidis; Athanasios Katsaounis; Dimitrios Giannakidis; Charilaos Koulouris; Zoi Aidoni; Nikolaos Michalopoulos; Paul Zarogoulidis; Isaak Kesisoglou; Aris Ioannidis; Anastasios Vagionas; Konstantinos Romanidis; Panagoula Oikonomou; Vasilios Grosomanidis
Journal:  Medicina (Kaunas)       Date:  2019-11-28       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.